Just last week, we highlighted an opportunity in Viking Therapeutics (VKTX).


At the time, it traded at about $26.50 as it initiated its VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. All as the company progresses with both oral and subcutaneous formulations for the potential treatment.

Today, the VKTX stock is up to $30.20 and is still a strong buy.

Helping, analysts at BTIG just reiterated a buy rating on the stock with a $125 price target thanks to the latest trials. 

Start pulling in more than a part time job. In about 5-10 min a day you can make more than most sidehustles. Click here to check it out for just $1.

As noted by Investing.com, “BTIG expressed encouragement about Viking’s execution across its obesity franchise, noting the firm sees ‘tremendous value’ in the company’s portfolio of obesity and metabolic disease programs. The research firm also highlighted upcoming oral VK2735 data from the VENTURE study expected in the second half of 2025.”

Investors may want to take advantage of the VKTX stock while it’s still this cheap.

Sincerely,

Ian Cooper